梁子彬课题组科研博士后

1. 课题组介绍：
梁子彬博士毕业于中山大学中山医学院，2011年在中大中山医学院从事肿瘤学、神经生物学、纳米成像研究。2016年11月获邀访问美国加州大学洛杉矶分校（UCLA）、出席第46届美国神经科学SfN年会并做学术报告；2019年出席CSTRO中美学术交流口头报告；2020年美国ASCO大会学术报告。与美国加州大学洛杉矶分校保持长期合作，致力于新型纳米材料在肿瘤靶向成像及治疗效果的研究。主持国自然面上项目1项，省部级课题3项，中山大学及厅局级级项目4项。现任：中大五院科研科科长、重点项目管理办公室项目主任（兼）、五院“精准放疗创新技术工作室”领衔人。因科研工作需要，招聘博士后3名。

2. 课题组研究方向：
梁子彬课题组的研究将以肿瘤学、放射肿瘤学为出发点，从事多功能纳米成像、疗效以及放疗敏感性、放疗抗拒及副作用的探索，主要研究方向为：（一）纳米药物在肿瘤中的作用规律和优化策略；（二）器官放射性损伤的药物保护作用和机制探索。（三）肿瘤临床治疗新策略、新方案的探索与实施。课题组在ACS系列刊物发表原创科研论文多篇，申请国内专利3项，启动IIT临床试验4项。学术成果被包括SfN、CSTRO及ASCO多次报道，部分技术及成果已进入临床前和临床研究。

3. 要求和工作内容：
已经或者将在近期获得肿瘤学、生物药学、细胞生物学、分子生物学、生物化学或相关领域博士学位，优先考虑对课题组研究方向具有浓厚兴趣的和研究背景契合的申请人；以第一作者发表过SCI论文；具备良好的独立科研能力、英文读写能力；喜欢实验室工作环境，具有团队协作精神。


Announcement for Recruiting Postdoctoral Researchers
of Zibin Liang Research Group from The Fifth Affiliated Hospital of SunYat-sen University
1. Introduction about us
Dr. Zibin Liang graduated from Zhongshan Medical School of Sun Yat-senUniversity. In 2011, he engaged in oncology, neurobiology and nanoimaging research in the laboratory. In November 2016, he was invited tovisit UCLA, attended the 46th annual SfN conference. In 2019, heattended CSTRO's oral report on Sino US academic exchanges. Academicreport of 2020 American ASCO conference. It has maintained long-termcooperation with UCLA, and is committed to the research on the effect ofnew nano materials in tumor targeted imaging and treatment. 1 nationalnatural general project, 3 provincial and ministerial projects, and 4office and bureau level projects. Currently, he is the Chief of theScientific Research Section, the Project Director (concurrently) of theKey Project Management Office, and the leader of the "PrecisionRadiotherapy Innovation Technology Studio".
Due to the needs of scientific research, 3 postdoctors will be recruited.
2. Research direction
Liang's research group will base on the oncology, radiation oncology.The main research directions are: (1) The role and optimization strategyof nano drugs in cancer; (2) Exploration of drug protection andmechanism of organ radiation injury. (3) Exploration and implementationof new strategies and plans for tumor clinical treatment. The researchgroup has published many original scientific research papers in ACSseries publications, also applied for 3 domestic patents and launched 4IIT clinical trials. Academic achievements have been reported by SfN,CSTRO and ASCO for many times, and some technologies and achievementshave entered preclinical and clinical research.
3. Requirements and work contents:
Applicants who have obtained or will obtain Ph.D. degrees in oncology,biopharmaceutics, cell biology, molecular biology, bio-chemistry orrelated fields in the near future will be given priority to those whohave strong interest in the research direction of the research group andfit the research background. Published SCI papers as the first author.Good independent scientific research ability and English reading andwriting ability.
4. Benefits a